Neuren Pharmaceuticals Limited (AU:NEU)
ASX:NEU
Holding AU:NEU?
Track your performance easily

Neuren Pharmaceuticals Limited (NEU) Ownership - Who Owns Neuren Pharmaceuticals Limited?

159 Followers

Neuren Pharmaceuticals Limited (NEU) Ownership Overview

0.02%2.81%<0.01%2.99%94.17%
<0.01% Other Institutional Investors
2.99% ETFs
94.17% Public Companies and
Individual Investors
The ownership structure of Neuren Pharmaceuticals Limited (AU:NEU) stock is a mix of institutional, retail, and individual investors. Approximately 5.81% of the company’s stock is owned by Institutional Investors, 0.02% is owned by Insiders, and 94.17% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 16, 2024
Joseph Basile
Non Executive,director
xxxxxxxxxxxxx
AU$100766
Jun 13, 2024
Joseph Basile
Non Executive,director
xxxxxxxxxxxxx
AU$97450

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
1,896,600Institution1.46%15,343,494
1,501,882Institution1.15%12,150,225
1,458,441Institution1.12%11,798,788
920,229Institution0.71%7,444,653
577,969Institution0.44%4,675,769
481,489Institution0.37%3,895,246
201,087Institution0.15%1,626,794
181,090Institution0.14%1,465,018
55,146Institution0.04%446,131
54,161Institution0.04%438,162

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
1,501,882Institution1.15%12,150,225
920,229Institution0.71%7,444,653
577,969Institution0.44%4,675,769
481,489Institution0.37%3,895,246
54,161Institution0.04%438,162
50,355Institution0.04%407,372
32,921Institution0.03%266,331
24,487Institution0.02%198,100
4,504Institution<0.01%36,437
3,358Institution<0.01%27,166

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
924,822Institution0.71%9,630,568
739,808Institution0.57%5,980,749
379,140Institution0.29%3,948,147
372,139Institution0.29%3,008,443
201,087Institution0.15%1,621,724
176,228Institution0.14%1,424,661
135,901Institution0.10%1,415,195
142,159Institution0.11%1,149,241
91,346Institution0.07%736,686
69,063Institution0.05%556,978

FAQ

Who Owns Neuren Pharmaceuticals Limited (AU:NEU)?
According to the latest TipRanks data, approximately <0.01% of the company's stock is held by institutional investors, 0.02% is held by insiders, and 94.17% is held by retail investors.
    What percentage of Neuren Pharmaceuticals Limited (AU:NEU) stock is held by institutional investors?
    According to the latest TipRanks data, approximately <0.01% of Neuren Pharmaceuticals Limited (AU:NEU) stock is held by institutional investors.
      What percentage of Neuren Pharmaceuticals Limited (AU:NEU) stock is held by retail investors?
      According to the latest TipRanks data, approximately 94.17% of Neuren Pharmaceuticals Limited (AU:NEU) stock is held by retail investors.
        Who owns the most shares of Neuren Pharmaceuticals Limited (AU:NEU)?
        iShares owns the most shares of Neuren Pharmaceuticals Limited (AU:NEU).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis